Allogene CEO David Chang to step down after eight years; former Esperion chief joins Phlow
read at Endpoints ↗Neutral
Longtime Allogene chief executive David Chang announced he will leave the role at the end of June, concluding an eight‑year tenure leading the cell‑therapy developer.
The company said a successor will take over, though the name was not disclosed in the brief notice. Chang’s departure marks a leadership transition as Allogene continues its pipeline development.
Separately, Phlow introduced its new chief executive, a former CEO of Esperion, signaling a fresh leadership direction for the biotech firm.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “David Chang to hand over the reins at Allogene; Ex-Esperion CEO gets started at Phlow”
read at Endpoints ↗95 words · retrieved Jun 3
comments(0)
5-min edit window · permanent after that